Latest news with #PolyMedicureLtd
Economic Times
06-07-2025
- Business
- Economic Times
Stock Radar: Poly Medicure stock looks attractive for short-term gains; still down 30% from highs
Poly Medicure Ltd, part of the medical equipment industry, is showing signs of bottoming out after falling more than 30% from traders with a high-risk profile can look to buy stock for a target of Rs 2,400-2,610 in the next few weeks, suggest medical equipment stock hit a high of Rs 3,350 on 1st July 2024, but it failed to hold the momentum. It closed at Rs 2,268 on July 2, 2025 which translates into a downside of
Business Upturn
07-05-2025
- Business
- Business Upturn
Poly Medicure shares surge 3% as Q4 revenue rises 16.6% YoY to Rs 441 crore
By Aman Shukla Published on May 7, 2025, 10:08 IST Poly Medicure Ltd. witnessed a 3% surge in its share price during morning trade following the release of its robust Q4 results. The company reported impressive year-on-year growth across key financial metrics for the quarter. As of 10:06 AM, the shares were trading 3.37% higher at Rs 2,875.00. For Q4, Poly Medicure posted a 16.6% increase in revenue, reaching Rs 441 crore compared to Rs 378 crore in the same period last year. The company's EBITDA saw a notable rise of 23.8%, amounting to Rs 119 crore, up from Rs 96 crore last year. This improvement in profitability was further reflected in the company's EBITDA margin, which expanded to 27%, compared to 25.5% in the previous year. Poly Medicure's net profit also soared by 35.3%, reaching Rs 92 crore as compared to Rs 68 crore in Q4 FY24, demonstrating strong operational efficiency and market demand. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
06-02-2025
- Business
- Yahoo
Poly Medicure Ltd (BOM:531768) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Release Date: February 03, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Poly Medicure Ltd (BOM:531768) reported a significant revenue growth of 24.9% in Q3 FY25 compared to the previous year. The company's return on capital employed (ROCE) is strong at 23.9%, indicating efficient use of capital. Net cash available is substantial at approximately 1,074 crores, providing a solid financial foundation for future investments. The company has expanded its workforce, adding 64 new employees in sales, particularly in the cardiology and critical care divisions. Poly Medicure Ltd (BOM:531768) received the CII Industrial Innovation Awards 2024 and the CII International Intellectual Property Awards 2024, highlighting its commitment to innovation. The company faces challenges in the dialysis business, with installation targets not being met as expected. Gross margins have seen a decline, attributed to changes in revenue mix, which could impact profitability. The company has minimal hedging on foreign exchange, which could expose it to currency fluctuations. The new product lines in cardiology and critical care are still in early stages and may take 2-3 years to significantly impact revenue. There is uncertainty regarding the impact of potential US tariffs on Chinese and Mexican exports, which could affect market dynamics. Warning! GuruFocus has detected 1 Warning Sign with BOM:531768. Q: Can you provide more details about the drug-eluting stent market and how your product compares to competitors? A: We have just entered the market with a US-approved stent. Our competitive edge lies in manufacturing everything in-house, including the balloon, which most companies import. Our stent offers superior maneuverability, but it will take time to complete clinical trials and fully commercialize the product. We are confident in our approach but cannot provide a revenue timeline yet. - Managing Director Q: How will the dialysis machine business impact your margin profile in the future? A: The dialysis business is relatively new, about five years old, compared to our 25-year-old infusion business. As we ramp up capacity and sell more products, operational costs will decrease, improving margins. We aim to achieve PLI (Production Linked Incentive) benefits by FY26, which will further contribute to margins. - Managing Director Q: Can you clarify the strategy behind entering the stent market, given it's under price control? A: The price control is at the upper end of the segment, not the lower end. There's a significant margin between the ex-factory price and the finished product price. The average stent price in India is around ?10,000 to ?12,000, while the price control is at ?40,000. We operate below the ceiling price, ensuring a healthy margin. - Managing Director Q: What is the growth trajectory for the renal business, and what market share do you aim to achieve? A: We expect the renal business to grow faster in the coming years as we replace imported products. The government has increased reimbursement rates for dialysis, and standalone dialysis clinics are now allowed, boosting demand. We aim to capture 20-25% market share by 2030. - Managing Director Q: How do you view the potential impact of US tariffs on Chinese and Mexican exports? A: These are essential products, and US hospitals cannot run out of them. Tariffs may increase costs for patients or hospitals but won't stop purchases. We don't foresee a risk of dumping in other markets, as consumption levels remain constant. - Managing Director For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
